Contributions
Abstract: P593
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Background: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system with heterogenic disease course, but the role of biomarkers in use to predict clinical outcome is still debated.
Objective: Our objective was to evaluate levels of NfL in CSF of patients with MS in relation to clinical progression of disease as measured by EDSS over a 10-year period.
Material and methods: Newly diagnosed patients with MS between 1998 and 2000 in Rogaland and Hordaland, western Norway were asked to participate. Patients underwent a lumbar puncture and clinical assessment at baseline, and subsequent clinical assessments after five and 10 years. The CSF was analyzed using the commercially available Uman Diagnostics NF-light® ELISA kit.
Results: Forty-four patients consented for lumbar puncture and were included with a mean age of 41.9 years at inclusion, and 68% were females. Thirty-five patients (80%) had a relapsing-remitting course of disease at time of inclusion. Male patients had higher mean concentrations of NfL (1661 ng/L) compared to 546 ng/L for female patients (p=0.004). Baseline level of NfL was significantly correlated with EDSS at five year follow up (r=0,298, p=0,026), but not with EDSS at baseline (r=0.247, p 0.053) or EDSS at ten year follow up (r=0.2, p=0.062). Patients who converted from RRMS to a secondary progressive form (SPMS) had a statistically significant higher mean concentration of NfL at baseline compared to those that remained as RRMS (1777.8 ng/L vs 693.2 ng/L , p=0.015).
Conclusion: Level of NfL quantified in CSF at the time of diagnosis correlated with clinical progression of MS as measured by EDSS after five years, and may predict conversion from RRMS to SPMS.
Disclosure:
Alok Bhan: Nothing to disclose.
Cecilie Jacobsen: Nothing to disclose.
Kjell-Morten Myhr:KM. Served on scientific advisory boards from Novartis Norway, Biogen Idec, Genzyme and Roche; received speaker honoraria, Genzyme, Sanofi-Aventis, Novartis, Biogen Idec and Teva; and received unrestricted research support from, Sanofi-Aventis, Novartis, Biogen Idec, and the Norwegian MS Society.
Harald Nyland: Nothing to disclose.
Kirsten Lode: Nothing to disclose.
Elisabeth Farbu: Speaker honoraria from Genzyme, Novartis, Teva, Biogen, and advisory boards: Novartis, Genzyme, Biogen.
Abstract: P593
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Background: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system with heterogenic disease course, but the role of biomarkers in use to predict clinical outcome is still debated.
Objective: Our objective was to evaluate levels of NfL in CSF of patients with MS in relation to clinical progression of disease as measured by EDSS over a 10-year period.
Material and methods: Newly diagnosed patients with MS between 1998 and 2000 in Rogaland and Hordaland, western Norway were asked to participate. Patients underwent a lumbar puncture and clinical assessment at baseline, and subsequent clinical assessments after five and 10 years. The CSF was analyzed using the commercially available Uman Diagnostics NF-light® ELISA kit.
Results: Forty-four patients consented for lumbar puncture and were included with a mean age of 41.9 years at inclusion, and 68% were females. Thirty-five patients (80%) had a relapsing-remitting course of disease at time of inclusion. Male patients had higher mean concentrations of NfL (1661 ng/L) compared to 546 ng/L for female patients (p=0.004). Baseline level of NfL was significantly correlated with EDSS at five year follow up (r=0,298, p=0,026), but not with EDSS at baseline (r=0.247, p 0.053) or EDSS at ten year follow up (r=0.2, p=0.062). Patients who converted from RRMS to a secondary progressive form (SPMS) had a statistically significant higher mean concentration of NfL at baseline compared to those that remained as RRMS (1777.8 ng/L vs 693.2 ng/L , p=0.015).
Conclusion: Level of NfL quantified in CSF at the time of diagnosis correlated with clinical progression of MS as measured by EDSS after five years, and may predict conversion from RRMS to SPMS.
Disclosure:
Alok Bhan: Nothing to disclose.
Cecilie Jacobsen: Nothing to disclose.
Kjell-Morten Myhr:KM. Served on scientific advisory boards from Novartis Norway, Biogen Idec, Genzyme and Roche; received speaker honoraria, Genzyme, Sanofi-Aventis, Novartis, Biogen Idec and Teva; and received unrestricted research support from, Sanofi-Aventis, Novartis, Biogen Idec, and the Norwegian MS Society.
Harald Nyland: Nothing to disclose.
Kirsten Lode: Nothing to disclose.
Elisabeth Farbu: Speaker honoraria from Genzyme, Novartis, Teva, Biogen, and advisory boards: Novartis, Genzyme, Biogen.